Lipidor has announced the strengthening of its management team with the appointment of Anders Hagman as Chief Development Officer. Hagman will assume the role as of 1 October 2020.
The company’s goal is to establish the company's Akvano technology as the leading formulation platform for the development of skin medicines.
Anders Hagman has a PhD and Master's degree in Analytical Chemistry from Stockholm University, and more than 30 years of experience in the life science sector. His career has included major international pharmaceutical companies such as Pharmacia, AstraZeneca, Recipharm, as well as smaller companies such as Cobra Biologics. He joins Lipidor from his own business as a CMC consultant with expertise in chemistry, manufacturing and control from early research to clinical Phase III.
Anders Hagman will strengthen the organization, both in day-to-day operations and in the strategic development work with responsibility for the entire product chain from start to finish, and will report to the CEO.
“I am very pleased with the recruitment of Anders Hagman for the new position as Chief Development Officer. Anders' background is a great match for the needs of Lipidor and his solid experience and expertise in drug development will be a valuable complement to the organization,” says Ola Holmlund, CEO of Lipidor AB.
